Compare UTL & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UTL | TBPH |
|---|---|---|
| Founded | 1984 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 906.9M | 824.9M |
| IPO Year | 1995 | 2013 |
| Metric | UTL | TBPH |
|---|---|---|
| Price | $51.73 | $16.34 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $56.50 | $18.40 |
| AVG Volume (30 Days) | 82.8K | ★ 282.6K |
| Earning Date | 05-04-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.65% | N/A |
| EPS Growth | 1.37 | ★ 279.13 |
| EPS | ★ 1.85 | N/A |
| Revenue | ★ $536,000,000.00 | $15,386,000.00 |
| Revenue This Year | $5.43 | $8.46 |
| Revenue Next Year | $4.22 | N/A |
| P/E Ratio | $27.78 | ★ N/A |
| Revenue Growth | ★ 8.33 | N/A |
| 52 Week Low | $45.11 | $9.10 |
| 52 Week High | $55.12 | $21.03 |
| Indicator | UTL | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 50.99 | 46.74 |
| Support Level | $51.05 | $16.14 |
| Resistance Level | $53.65 | $17.21 |
| Average True Range (ATR) | 1.20 | 0.38 |
| MACD | 0.13 | -0.07 |
| Stochastic Oscillator | 62.30 | 29.31 |
Unitil Corp through its subsidiaries engages in the distribution of electricity and natural gas in its service territories in the states of New Hampshire, Massachusetts and Maine. Its natural gas operations include gas distribution utility operations and interstate gas transmission pipeline operations. It also engages in interstate natural gas transmission pipeline company, operating approximately 85 miles of underground gas transmission pipeline located in Maine and New Hampshire. The company's segments include Electric and Gas.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.